Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells

Leukemia

Volumn 27, Issue 2, 2013, Pages 315-324

  Wang, R ^a   Xia, L ^a   Gabrilove, J ^a   Waxman, S ^a   Jing, Y ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ARSENIC TRIOXIDE; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEASOME; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BIOACCUMULATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HALF LIFE TIME; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; DOWN-REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; OXIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84873568965     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.180     Document Type: Article

References (55)

1. Park JH, Tallman MS. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park) 2011; 25: 733-741.
2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
3. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH et al. Combined effect of alltrans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269.
4. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
5. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
6. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-133.
7. Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 2010; 10: 504-510.
8. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
9. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 2004; 101: 4578-4583.
10. Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem 2009; 284: 12886-12895.
11. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009; 284: 18583-18587.
12. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67: 2908-2911.
13. Yin S, Wang R, Zhou F, Zhang H, Jing Y. Bcl-xl is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells. Mol Pharmacol 2011; 79: 1072-1083.
14. Dzhagalov St I, John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 2007; 109: 1620-1626.
15. Campbell CJ, Lee JB, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010; 116: 1433-1442.
16. Martelli AM, EVangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009; 18: 1333-1349.
17. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105: 10853-10858.
18. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
19. Mann KK, Colombo M, Miller Jr. WH. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther 2008; 7: 1680-1687.
20. Ramos AM, Fernandez C, Amran D, Sancho P, de Blas E, Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005; 105: 4013-4020.
21. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21: 749-760.
22. Opferman JT. Unraveling MCL-1 degradation. Cell Death Differ 2006; 13: 1260-1262.
23. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-733.
24. Yamada M, Hashinaka K, Inazawa J, Abe T. Expression of catalase and myeloperoxidase genes in hydrogen peroxide-resistant HL-60 cells. DNA Cell Biol 1991; 10: 735-742.
25. Fernandez-Checa JC, Kaplowitz N. The use of monochlorobimane to determine hepatic GSH levels and synthesis. Anal Biochem 1990; 190: 212-219.
26. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004; 23: 5301-5315.
27. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008; 118: 3003-3006.
28. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27: 4006-4017.
29. Culbert AA, Brown MJ, Frame S, Hagen T, Cross DA, Bax B et al. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 2001; 507: 288-294.
30. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3: 479-487.
31. Coe E, Schimmer AD. Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma 2008; 49: 1976-1981.
32. Bernardini S, Nuccetelli M, Noguera NI, Bellincampi L, Lunghi P, Bonati A et al. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. Ann Hematol 2006; 85: 681-687.
33. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
34. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000; 14: 431-438.
35. Akao Y, Yamada H, Nakagawa Y. Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 2000; 37: 53-63.
36. Sahara N, Takeshita A, Kobayashi M, Shigeno K, Nakamura S, Shinjo K et al. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway. Leuk Lymphoma 2004; 45: 987-995.
37. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998; 92: 1497-1504.
38. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-1968.
39. Goussetis DJ, Platanias LC. Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia. Clin Cancer Res 2010; 16: 4311-4312.
40. Pende M, Um SH, Mieulet V, Sticker M, Goss L, Mestan J et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinasedependent S6 kinase pathway. Mol Cell Biol 2004; 24: 3112-3124.
41. Huber S, Oelsner M, Decker T, zum Buschenfelde CM, Wagner M, Lutzny G et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25: 838-847.
42. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280: 35217-35227.
43. Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W et al. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther 2009; 8: 2406-2416.
44. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
45. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109.
46. Ramos AM, Fernandez C, Amran D, Esteban D, de Blas E, Palacios MA et al. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J Cell Physiol 2006; 209: 1006-1015.
47. Chiou JF, Tai CJ, Wang YH, Liu TZ, Jen YM, Shiau CY. Sorafenib induces preferential apoptotic killing of a drug-and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther 2009; 8: 1904-1913.
48. Chen D, Chan R, Waxman S, Jing Y. Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res 2006; 66: 11416-11423.
49. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003; 17: 931-940.
50. Iles KE, Liu RM. Mechanisms of glutamate cysteine ligase (GCL) induction by 4-hydroxynonenal. Free Radic Biol Med 2005; 38: 547-556.
51. Pattillo CB, Pardue S, Shen X, Fang K, Langston W, Jourd'heuil D et al. ICAM-1 cytoplasmic tail regulates endothelial glutathione synthesis through a NOX4/PI3-kinase-dependent pathway. Free Radic Biol Med 2010; 49: 1119-1128.
52. Chen ZH, Saito Y, Yoshida Y, Noguchi N, Niki E. Regulation of GCL activity and cellular glutathione through inhibition of ERK phosphorylation. Biofactors 2008; 33: 1-11.
53. Jang JH, Surh YJ. Bcl-2 attenuation of oxidative cell death is associated with upregulation of gamma-glutamylcysteine ligase via constitutive NF-kappaB activation. J Biol Chem 2004; 279: 38779-38786.
54. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
55. Rollig C, Brandts C, Shaid S, Hentrich M, Kramer A, Junghanss C et al. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk Lymphoma 2011; 53: 1062-1067.